C4 Therapeutics, Inc. - Common Stock — Liquidità (NASDAQ:CCCC) | MetaTrader

Apri il grafico completo Full chart

Financials

Panoramica Estratto Conto Statistiche

Trimestrale Annuale

Flusso di cassa derivante dalle attività operative -67.25 M-86.97 M-105.94 M-106.84 M-65.16 M-98.69 M -95.35 M Flussi di cassa derivanti dalle attività di investimento -190.5 M-189.34 M58.42 M158.35 M-51.27 M-8.6 M -21.57 M Liquidità derivante dalle attività di finanziamento 348.93 M171.4 M1.15 M45.49 M45.34 M126.4 M 126.91 M Liquidità libera -67.25 M-86.97 M-105.94 M-106.84 M-65.16 M-99.3 M -96.02 M

Notizie

Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?

C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates

LENZ Therapeutics, Inc. (LENZ) Reports Q1 Loss, Beats Revenue Estimates

Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Lags Revenue Estimates

C4 Therapeutics aggiorna lo statuto per designare i tribunali federali come sedi esclusive

What's Going On With C4 Therapeutics Stock Thursday? - C4 Therapeutics (NASDAQ:CCCC)

Le azioni di C4 Therapeutics salgono con l’espansione della partnership con Roche

C4 Therapeutics e Roche collaborano sui coniugati degradatori per il cancro

Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year?

C4 Therapeutics avvia trial di cemsidomide con elranatamab

Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice

Is BrightSpring Health Services, Inc. (BTSG) Stock Outpacing Its Medical Peers This Year?